Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| InMed Pharmaceuticals Inc.INM · Entity 8139 | Director · President & CEO | December 19, 2025 | December 19, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
InMed Pharmaceuticals Inc.
Report date December 19, 2025 · Filed December 19, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.29 · Expires 2030-12-18 | Direct | 49,050 |
Reported balance
After 2025-12-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-12-19 · Grant · Acquired 35,000 · Balance 49,050 F1: The options were granted on 12/19/2025 and will vest in equal installments monthly, in arrears, over 36 months (1/36 per month) |
Filing footnotes · ownership attribution and instrument terms
F1: The options were granted on 12/19/2025 and will vest in equal installments monthly, in arrears, over 36 months (1/36 per month)
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 19, 2025 Filed Dec 19, 2025 11:39 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | GrantEmployee Stock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0001213900-25-123625 · ownership.xml · derivative · entry 1 ADAMS ERIC A · CIK 0001817882 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,050 Underlying: Common shares · 35,000 shares Expires 2030-12-18 F1 · derivative.exercise_date: The options were granted on 12/19/2025 and will vest in equal installments monthly, in arrears, over 36 months (1/36 per month) Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 12:19 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | OtherEmployee Stock Option (Expiration) · Derivative | 250 | $0.00 Strike: $1,397.97 | $0.00 |
DisclosureSEC source: 0001213900-25-122647 · ownership.xml · derivative · entry 1 ADAMS ERIC A · CIK 0001817882 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,050 Underlying: Common shares · 250 shares Expires 2025-12-15 F1 · derivative.exercise_price: Converted from the Canadian dollar exercise price of C$1,925.00 using an exchange rate of C$1.3770 = $US1.00 Read SEC document |
| December 20, 2024 Filed Dec 23, 2024 09:20 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | GrantEmployee Stock Option (Right to Buy) · Derivative | 6,250 | $0.00 Strike: $4.14 | $0.00 |
DisclosureSEC source: 0001213900-24-111552 · ownership.xml · derivative · entry 1 ADAMS ERIC A · CIK 0001817882 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,300 Underlying: Common shares · 6,250 shares Expires 2029-12-19 F1 · derivative.exercise_date: The options were granted on 12/20/2024 and will vest in equal installments monthly over 36 months (1/36 per month). F2 · balance_after: On November 14, 2024, the common stock of InMed was reverse split on a 1-for-20 basis. This number reflects that reverse stock split. Read SEC document |
| May 27, 2024 Filed May 28, 2024 16:26 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | OtherEmployee Stock Option (Expiration) · Derivative | 1,139 | $0.00 Strike: $263.18 | $0.00 |
DisclosureSEC source: 0001213900-24-047094 · ownership.xml · derivative · entry 1 ADAMS ERIC A · CIK 0001817882 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 161,000 Underlying: Common shares · 1,139 shares Expires 2024-05-27 F1 · derivative.exercise_price: Converted from the Canadian dollar exercise price of C$358.875 using an exchange rate of C$1.3636 (as of May 27th, 2024) = $US1.00 Read SEC document |
| February 20, 2024 Filed Feb 21, 2024 14:58 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | PurchaseCommon Stock | 41,600 | $0.36 | $14,921.92 |
DisclosureSEC source: 0001213900-24-015703 · ownership.xml · nonDerivative · entry 1 ADAMS ERIC A · CIK 0001817882 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,959 Read SEC document |
| December 23, 2023 Filed Dec 26, 2023 13:07 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | GrantEmployee Stock Option (Right to Buy) · Derivative | 136,000 | $0.00 Strike: $0.37 | $0.00 |
DisclosureSEC source: 0001213900-23-098489 · ownership.xml · derivative · entry 1 ADAMS ERIC A · CIK 0001817882 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 162,139 Underlying: Common shares · 136,000 shares Expires 2028-12-22 F1 · derivative.exercise_date: The options were granted on 12/23/2023 and will vest in equal installments monthly over 36 months (1/36 per month). Read SEC document |
| May 16, 2023 Filed May 16, 2023 17:58 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | OtherEmployee Stock Option (Expiration) · Derivative | 1,818 | $0.00 Strike: $623.93 | $0.00 |
DisclosureSEC source: 0001213900-23-040577 · ownership.xml · derivative · entry 1 ADAMS ERIC A · CIK 0001817882 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,139 Underlying: Common shares · 1,818 shares Expires 2023-05-16 F1 · derivative.exercise_price: Converted from the Canadian dollar exercise price of C$841.50 using an exchange rate of C$1.3487 = $US1.00 Read SEC document |
| March 08, 2023 Filed Mar 9, 2023 15:43 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | OtherEmployee Stock Option (Expiration) · Derivative | 545 | $0.00 Strike: $927.64 | $0.00 |
DisclosureSEC source: 0001213900-23-018866 · ownership.xml · derivative · entry 1 ADAMS ERIC A · CIK 0001817882 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,957 Underlying: Common shares · 545 shares Expires 2023-03-08 F1 · derivative.exercise_price: Converted from the Canadian dollar exercise price of C$1,278.75 using an exchange rate of C$1.3785 = $US1.00 Read SEC document |
| December 16, 2022 Filed Dec 19, 2022 16:50 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | GrantEmployee Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $1.78 | $0.00 |
DisclosureSEC source: 0001213900-22-080967 · ownership.xml · derivative · entry 1 ADAMS ERIC A · CIK 0001817882 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,502 Underlying: Common shares · 15,000 shares Expires 2027-12-15 F1 · derivative.exercise_date: The options were granted on 12/16/2022 and will vest as follows: 25% of stock options will vest 6 months after the date of Grant; 25% of stock options will vest 12 months after the date of the Grant; 25% stock options will vest 18 months after the date of the Grant; and 25% stock options will vest 24 months after the date of the Grant. F2 · balance_after: On September 7, 2022, the common stock of InMed was reverse split on a 1-for-25 basis. This number reflects that reverse stock split. Read SEC document |
| November 14, 2022 Filed Nov 15, 2022 19:44 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | GrantEmployee Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $2.78 | $0.00 |
DisclosureSEC source: 0001213900-22-072920 · ownership.xml · derivative · entry 1 ADAMS ERIC A · CIK 0001817882 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,502 Underlying: Common shares · 15,000 shares Expires 2027-11-13 F1 · derivative.exercise_date: The options were granted on 11/14/2022 and will vest as follows: 25% of stock options will vest 6 months after the date of Grant; 25% of stock options will vest 12 months after the date of the Grant; 25% stock options will vest 18 months after the date of the Grant; and 25% stock options will vest 24 months after the date of the Grant. F2 · balance_after: On September 7, 2022, the common stock of InMed was reverse split on a 1-for-25 basis. This number reflects that reverse stock split. Read SEC document |
| November 14, 2022 Filed Nov 18, 2022 19:34 UTC Amendment | InMed Pharmaceuticals Inc. INM · Entity 8139 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $2.78 | $0.00 |
DisclosureSEC source: 0001213900-22-073943 · ownership.xml · derivative · entry 1 ADAMS ERIC A · CIK 0001817882 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,502 Underlying: Common shares · 15,000 shares Expires 2027-11-13 F3 · kind: On November 14, 2022, the reporting person reported the grant of an employee stock option to buy 15,000 shares of the Issuer's common stock at an exercise price of $2.78 per share. Such employee stock option was issued in error and has been cancelled. As of November 18, 2022, the reporting person beneficially owns 13,502 derivative securities of the Issuer. F3 · shares: On November 14, 2022, the reporting person reported the grant of an employee stock option to buy 15,000 shares of the Issuer's common stock at an exercise price of $2.78 per share. Such employee stock option was issued in error and has been cancelled. As of November 18, 2022, the reporting person beneficially owns 13,502 derivative securities of the Issuer. F1 · derivative.exercise_date: The options were granted on 11/14/2022 and will vest as follows: 25% of stock options will vest 6 months after the date of Grant; 25% of stock options will vest 12 months after the date of the Grant; 25% stock options will vest 18 months after the date of the Grant; and 25% stock options will vest 24 months after the date of the Grant. F2 · balance_after: On September 7, 2022, the Issuer's common stock was reverse split on a 1-for-25 basis. This number reflects that reverse stock split. F3 · balance_after: On November 14, 2022, the reporting person reported the grant of an employee stock option to buy 15,000 shares of the Issuer's common stock at an exercise price of $2.78 per share. Such employee stock option was issued in error and has been cancelled. As of November 18, 2022, the reporting person beneficially owns 13,502 derivative securities of the Issuer. Read SEC document |
| June 02, 2022 Filed Jun 2, 2022 14:50 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | OtherEmployee Stock Option (Expiration) · Derivative | 13,636 | $0.00 Strike: $11.75 | $0.00 |
DisclosureSEC source: 0001213900-22-030914 · ownership.xml · derivative · entry 1 ADAMS ERIC A · CIK 0001817882 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 337,576 Underlying: Common shares · 13,636 shares Expires 2022-06-02 F1 · derivative.exercise_price: Converted from the Canadian dollar exercise price of C$14.85 using an exchange rate of C$1.2639 = $US1.00 Read SEC document |
| April 14, 2022 Filed Apr 18, 2022 11:46 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | PurchaseCommon Stock | 14,160 | $0.89 | $12,659.04 |
DisclosureSEC source: 0001213900-22-020314 · ownership.xml · nonDerivative · entry 1 ADAMS ERIC A · CIK 0001817882 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,003 Read SEC document |
| April 13, 2022 Filed Apr 13, 2022 21:43 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | PurchaseCommon Stock | 8,560 | $0.85 | $7,276.00 |
DisclosureSEC source: 0001213900-22-019688 · ownership.xml · nonDerivative · entry 1 ADAMS ERIC A · CIK 0001817882 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,843 Read SEC document |
| January 24, 2022 Filed Jan 24, 2022 16:18 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | OtherEmployee Stock Option (Expiration) · Derivative | 60,606 | $0.00 Strike: $2.89 | $0.00 |
DisclosureSEC source: 0001213900-22-003333 · ownership.xml · derivative · entry 2 ADAMS ERIC A · CIK 0001817882 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 351,212 Underlying: Common shares · 60,606 shares Expires 2022-01-24 F2 · derivative.exercise_price: Converted from the Canadian dollar exercise price of C$3.63 using an exchange rate of C$1.2554 = $US1.00 Read SEC document |
| January 24, 2022 Filed Jan 24, 2022 16:18 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | OtherEmployee Stock Option (Expiration) · Derivative | 60,606 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001213900-22-003333 · ownership.xml · derivative · entry 1 ADAMS ERIC A · CIK 0001817882 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 411,818 Underlying: Common shares · 60,606 shares Expires 2022-01-24 F1 · derivative.exercise_price: Converted from the Canadian dollar exercise price of C$2.64 using an exchange rate of C$1.2554 = $US1.00 Read SEC document |
| October 18, 2021 Filed Oct 19, 2021 18:20 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | GrantEmployee Stock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $1.40 | $0.00 |
DisclosureSEC source: 0001213900-21-053583 · ownership.xml · derivative · entry 1 ADAMS ERIC A · CIK 0001817882 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 472,424 Underlying: Common shares · 125,000 shares Expires 2026-10-17 F1 · derivative.exercise_date: The options were granted on 10/18/2021 and will vest as follows: 25% of stock options will vest 6 months after the date of Grant; 25% of stock options will vest 12 months after the date of the Grant; 25% stock options will vest 18 months after the date of the Grant; and 25% stock options will vest 24 months after the date of the Grant. Read SEC document |
| September 29, 2021 Filed Sep 30, 2021 13:39 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | PurchaseCommon Stock | 8,800 | $1.73 | $15,224.00 |
DisclosureSEC source: 0001213900-21-050751 · ownership.xml · nonDerivative · entry 1 ADAMS ERIC A · CIK 0001817882 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,283 Read SEC document |
| September 28, 2021 Filed Sep 29, 2021 14:00 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | PurchaseCommon Stock | 11,400 | $1.75 | $19,984.20 |
DisclosureSEC source: 0001213900-21-050522 · ownership.xml · nonDerivative · entry 1 ADAMS ERIC A · CIK 0001817882 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,483 Read SEC document |
| December 16, 2020 Filed Dec 18, 2020 06:08 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | GrantEmployee Stock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $3.02 | $0.00 |
DisclosureSEC source: 0001213900-20-043355 · ownership.xml · derivative · entry 1 ADAMS ERIC A · CIK 0001817882 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common shares · 125,000 shares Expires 2025-12-15 F1 · derivative.exercise_price: The Canadian exercise price of C$3.85 was converted into U.S. dollars using an exchange rate of C$1.2753 = US$1.00. F2 · derivative.exercise_date: The options were granted on 12/16/2020 and will vest as follows: 25% on 6/16/2021; 25% on 12/16/2021; 25% on 6/16/2022; and 25% on 12/16/2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.